December 7, 2022

Novartis and MMV Announce Enhanced Malaria Treatment

Staff Writer December 7, 2022

Trustworthy and indepth news stories are more important now than ever.
Support our newsroom by MAKING A CONTRIBUTION HERE

Treatment of malaria is scheduled to get a new boost with a therapy that seeks to clear the infection as well as blocking transmission of parasites that cause malaria.

Novartis and Medicines for Malaria Venture (MMV) have announced a shift to phase3 study for novel non-artemisinin combinations to treat uncomplicated malaria.

According to scientists involved, this combination contains an optimized formulation of lumefantrine- it can be administered once daily unlike the usual twice-daily administration.

The new treatment is expected to help Rwanda’s relentless efforts in the fight against Malaria coupled with growing resistance to current malaria treatments.

According to Rwanda Biomedical Centre, the country’s health implementation agency, malaria incidence dropped from 400 per 1000 in 2016 to 148 per 1000 in 2020.

The agency says the country has continued to witness a decrease in malaria cases from 4.8 million in 2017 to 1.8 million in 2020, a decrease in severe malaria from 18,000 in 2016 to 3,000 in 2020. Malaria related deaths decreased from 700 in 2016 to 148 deaths in 2020.

According to Novartis and Medicines for Malaria Venture (MMV), Malaria is primarily treated with artemisinin-based combination therapies (ACTs) such as artemether-lumefantrine. ACTs are still highly effective and well tolerated.

However, Novartis and MMV have warned that the increased frequency by which parasites with a slower response to artemisinin are observed in some parts of Eastern Africa (Rwanda, Uganda, and the Horn of Africa) points to an urgent need to develop a new non-artemisinin class of antimalarials to avoid a return to the high levels of childhood mortality last seen in the 1990s.

Janvier Murenzi a community health worker in Bidudu village, Kiziguro sector in Gatsibo district says, his 12year old son contracted malaria in September, “I gave him the dose as required but he didn’t get well. I had to change to a stronger dose. That’s when he healed,” he said, adding that the current anti malaria medicine is not effective due to increased resistance.

Murenzi also said that at least every month he handles over ten cases for Malaria patients.

“If there is new and stronger medicine against Malaria, we will possibly eradicate it,” he said.

“The emergence of artemisinin resistance demands urgent action to develop new antimalarials. We need non-artemisinin-based medicines with novel mechanisms of action against resistant parasites, and simple, easy-to-follow dosing schedules to help increase treatment adherence,” said Dr Sujata Vaidyanathan, Head Global Health Development Unit, Novartis.

“The earlier we have new compounds and the faster the world adopts them, the better chance we stand of beating resistance,” noted Dr Sujata.

Dr. Timothy Wells, Chief Scientific Officer, MMV says, “we are increasingly seeing parasites with decreased sensitivity to artemisinin, even in Africa.”

“If the Phase 3 trial is successful, this new combination will increase the number of options available to countries and help save the lives of children at risk of this devastating disease,” said Dr Timothy Wells.

According to Novartis and MMV, the Phase 3 pivotal trial is planned to  start in 2023. It will compare the efficacy of ganaplacide/lumefantrine-SDF to the current ‘gold standard’ artemether-lumefantrine.

The trial will be conducted in collaboration with the WANECAM 2 consortium, and will include partner clinical sites in Burkina Faso, Mali, Gabon and Niger as well as other sites in sub-Saharan Africa.

Both Phase 2 and 3 studies receive funding from the European and Developing Countries Clinical Trials Partnership (EDCTP), which is supported by the European Union.

It should be remembered that Kenya and other ten countries on the continent have been administering a pilot RTS,S/AS01 (RTS,S) malaria vaccine recommended by the WHO for children aged 6months to five years.

We can't do quality journalism without your support

Perhaps it goes without saying — but producing quality journalism isn't cheap. At a time when newsroom resources and revenue are declining, The Chronicles remains committed to "Serving Your Right To Know The Truth". Stand with us as we document Rwanda's remarkable journey for you and the future generation. Do you value our journalism? We can't do it without you. Show us with your support by CONTRIBUTING HERE.
Email your news TIPS to info@chronicles.rw or WhatsApp +250788351327.
You can also find us on Signal

Society
November 25, 2023
276 0

Celebrating World Diabetes Day with GT Foundation

Business
November 22, 2023
274 0

Agaciro Development Fund, Hinga Wunguke Partner to Strengthen Food Systems, Promote Agricultural Markets

Featured Stories
November 7, 2023
3 0

While Rwanda Wants Genocide Suspect Kayishema Extradited, Tanzania Isn’t Letting Go

Business
November 2, 2023
1 0

Launch of First Digital Employment Platform in EAC

120 Comments

  1. Hey! This post couldn’t be written any better!
    Reading this post reminds me of my previous room mate! He always kept talking about this.
    I will forward this post to him. Fairly certain he will have a good read.
    Thanks for sharing!

    Reply

  3. Hello, i believe that i noticed you visited my web site thus i came to go back the
    choose?.I am trying to find issues to enhance my web site!I suppose its good enough to use some of your ideas!!

    Reply

  6. Definitely believe that which you said. Your favorite justification seemed to be at the web the simplest thing to keep in mind of.

    I say to you, I definitely get irked at the same time as people think about
    issues that they plainly don’t recognise about.
    You controlled to hit the nail upon the top and also outlined out the whole thing
    without having side effect , people can take a signal.

    Will likely be again to get more. Thank you

    Reply

  7. Amazing! This blog looks exactly like my old one! It’s on a completely
    different topic but it has pretty much the same
    page layout and design. Wonderful choice of colors!

    Reply

  8. What you posted was very logical. However, what about this?
    suppose you composed a catchier title? I ain’t saying your information isn’t solid, however what if you added
    a post title that makes people want more? I mean Novartis and
    MMV Announce Enhanced Malaria Treatment – THE CHRONICLES
    is kinda vanilla. You could glance at Yahoo’s home page and watch how they create news titles to
    grab viewers to click. You might add a video or a picture or two to grab readers interested about everything’ve written. Just my opinion, it might bring your
    blog a little bit more interesting.

    Reply

  9. I’m really loving the theme/design of your website.
    Do you ever run into any internet browser compatibility problems?
    A few of my blog readers have complained about my site not working
    correctly in Explorer but looks great in Chrome.
    Do you have any solutions to help fix this problem?

    Reply

  11. Hello there! I just want to give you a huge thumbs up
    for your excellent info you have here on this post. I will
    be returning to your website for more soon.

    Reply

  12. Hey! Do you know if they make any plugins to protect against hackers?
    I’m kinda paranoid about losing everything I’ve worked hard on. Any suggestions?

    Reply

  14. Hiya! Quick question that’s entirely off topic. Do you know
    how to make your site mobile friendly? My blog looks weird when viewing from my iphone 4.
    I’m trying to find a template or plugin that might be
    able to resolve this issue. If you have any recommendations, please share.
    Appreciate it!

    Reply

  19. Aw, this was an extremely nice post. Finding the time and actual effort to make a very good article… but what can I say… I put things off
    a lot and never seem to get nearly anything done.

    Reply

  20. Your style is unique in comparison to other folks I have read stuff from.

    Many thanks for posting when you have the opportunity,
    Guess I will just bookmark this page.

    Reply

  22. I loved as much as you’ll receive carried out right here.

    The sketch is tasteful, your authored subject matter stylish.
    nonetheless, you command get got an edginess over that you wish be
    delivering the following. unwell unquestionably
    come more formerly again since exactly the same nearly a
    lot often inside case you shield this hike.

    Reply

  23. Hey there! Someone in my Myspace group shared this site with us so I came
    to give it a look. I’m definitely loving the information. I’m book-marking and will be tweeting this to my
    followers! Excellent blog and excellent style and design.

    Reply

  26. Hey, I think your site might be having browser compatibility issues.
    When I look at your blog site in Opera, it looks fine but when opening in Internet Explorer, it has
    some overlapping. I just wanted to give you a quick
    heads up! Other then that, superb blog!

    Reply

  29. Good post. I learn something totally new and challenging on blogs
    I stumbleupon on a daily basis. It’s always interesting to read content from other authors and practice something from their web
    sites.

    Reply

  31. Just want to say your article is as surprising.

    The clearness in your submit is simply nice and that i can suppose
    you’re an expert in this subject. Well with your permission let me to
    clutch your RSS feed to stay up to date with coming near near post.
    Thanks 1,000,000 and please continue the enjoyable work.

    Reply

  32. Generally I do not read article on blogs, but I would like to say that
    this write-up very pressured me to take a look
    at and do so! Your writing taste has been surprised
    me. Thanks, quite nice post.

    Reply

  34. Just want to say your article is as surprising. The clearness in your post is
    simply excellent and i could assume you’re an expert on this subject.

    Fine with your permission allow me to grab your feed to keep updated with forthcoming post.
    Thanks a million and please continue the enjoyable work.

    Reply

  35. You really make it seem so easy with your presentation but I
    find this matter to be really something which
    I think I would never understand. It seems too
    complex and very broad for me. I’m looking forward for your next post, I will try to get
    the hang of it!

    Reply

  36. After I initially left a comment I seem to have clicked on the -Notify me when new comments are added- checkbox and from now on every time a comment is added I recieve 4 emails with the exact same comment. There has to be a way you are able to remove me from that service? Cheers!

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *